Concepedia
Statistics
Publications
1
Citations
27
H-Index
Active since
2014
Publications per year
2014–2014
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders
KC Herold, SE Gitelman, Ehlers et al. · eScholarship (California Digital Library) · 2014 · 27 citations · Full text
1–1 of 1